Experienced in Richter Syndrome

Dr. Connie W. Batlevi

Oncology
1275 York Ave, Box 330, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Richter Syndrome
1275 York Ave, Box 330, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Connie Batlevi is an Oncologist in New York, New York. Dr. Batlevi is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1275 York Ave, Box 330, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Combination product, Drug
Study Drugs: Tazemetostat, Lenalidomide, Rituximab
Study Phase: Phase 3
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: August 19, 2025
Intervention Type: Diagnostic test, Other
Study Phase: Phase 1
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drugs: AUTO3, cyclophosphamide, fludarabine, pembrolizumab
Study Phase: Phase 1/Phase 2
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: N-Acetylcysteine
Study Phase: Phase 1
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Abexinostat
Study Phase: Phase 2
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: December 14, 2022
Intervention Type: Drug
Study Drugs: Copanlisib, Ibrutinib
Study Phase: Phase 1/Phase 2
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Enrollment Status: Completed
Publish Date: October 10, 2022
Intervention Type: Drug
Study Drugs: Buparlisib, Ibrutinib
Study Phase: Phase 1
View 5 Less Clinical Trials

60 Total Publications

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Journal: American journal of hematology
Published: October 01, 2024
Similar Doctors
Richard R. Furman
Elite in Richter Syndrome
Dr. Richard R. Furman
Hematology | Oncology
Elite in Richter Syndrome
Dr. Richard R. Furman
Hematology | Oncology

Weill Medical College Of Cornell

520 E 70th St, Suite 651, 
New York, NY 
 (0.1 miles away)
212-746-6575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Furman is a Hematologist and an Oncologist in New York, New York. Dr. Furman is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Lymphadenectomy.

Elite in Richter Syndrome
Dr. John N. Allan
Hematology Oncology | Oncology | Hematology
Elite in Richter Syndrome
Dr. John N. Allan
Hematology Oncology | Oncology | Hematology

Weill Medical College Of Cornell

520 E 70th St, 
New York, NY 
 (0.1 miles away)
646-962-2012
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Allan is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Allan has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Splenectomy.

Distinguished in Richter Syndrome
Dr. Nicole Lamanna
Oncology | Hematology
Distinguished in Richter Syndrome
Dr. Nicole Lamanna
Oncology | Hematology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (5.4 miles away)
212-305-9876
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nicole Lamanna is an Oncologist and a Hematologist in New York, New York. Dr. Lamanna is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Batlevi's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile